Nurix swings to quarterly net income of 549.81 million; revenue jumps to 673.06 million

• Nurix reported revenue of $673.06 million for the three months ended Aug. 31, 2026, up 8,426% year over year.
• Net income swung to $549.81 million, or $4.73 per diluted share, from a net loss of $86.42 million.
• Research and development expenses fell to $79.26 million, while general and administrative expenses rose to $34.35 million.
• The revenue increase was primarily due to $653.16 million of license revenue from the Roche collaboration and a $10 million Sanofi milestone.
• Management highlighted first patient dosed in the Phase 3 DAYBreak CLL-306 trial and cash of $1.1 billion with runway into 2H 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121605PRIMZONEFULLFEED9843991) on October 12, 2026, and is solely responsible for the information contained therein.